Literature DB >> 27655876

Gonadotropin-releasing hormone agonist against severe aggression in autism.

Robin M F van der Weiden1, Frans M Helmerhorst2, Tomas Eriksson3.   

Abstract

Aggression in patients with autism spectrum disorder (ASD) presents an important therapeutic challenge. Conventional treatment appears to be inadequate in a number of cases. The occurrence of severe aggressive symptoms since the inception of adolescence in a male patient with ASD suggested a hormonal influence by androgens. Conventional treatment with antipsychotic and antiepileptic drugs and benzodiazepines was ineffective. A subcutaneous long-acting gonadotropin-releasing hormone agonist (GnRH agonist) injection was given on a monthly basis resulting in a substantial improvement in his aggressive behaviour and renewed socialisation. 2016 BMJ Publishing Group Ltd.

Entities:  

Year:  2016        PMID: 27655876      PMCID: PMC5051425          DOI: 10.1136/bcr-2016-216378

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Cyproterone acetate in the treatment of aggression.

Authors:  F Thibaut; L Colonna
Journal:  Am J Psychiatry       Date:  1992-03       Impact factor: 18.112

2.  Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.

Authors:  Tomas Eriksson
Journal:  Int Clin Psychopharmacol       Date:  2007-01       Impact factor: 1.659

3.  Complementary and alternative treatments for autism part 2: identifying and avoiding non-evidence-based treatments.

Authors:  Alison Singer; Ramita Ravi
Journal:  AMA J Ethics       Date:  2015-04-01

4.  Sexual behaviors in autism: problems of definition and management.

Authors:  G M Realmuto; L A Ruble
Journal:  J Autism Dev Disord       Date:  1999-04

5.  A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders.

Authors:  David A Geier; Mark R Geier
Journal:  Neuro Endocrinol Lett       Date:  2006-12       Impact factor: 0.765

Review 6.  Pharmacological interventions for those who have sexually offended or are at risk of offending.

Authors:  Omer Khan; Michael Ferriter; Nick Huband; Melanie J Powney; Jane A Dennis; Conor Duggan
Journal:  Cochrane Database Syst Rev       Date:  2015-02-18

7.  A prospective assessment of androgen levels in patients with autistic spectrum disorders: biochemical underpinnings and suggested therapies.

Authors:  David A Geier; Mark R Geier
Journal:  Neuro Endocrinol Lett       Date:  2007-10       Impact factor: 0.765

8.  Medical Therapy for Inappropriate Sexual Behaviors in a Teen With Autism Spectrum Disorder.

Authors:  Loyal Coshway; Julia Broussard; Kruti Acharya; Karen Fried; Michael E Msall; John D Lantos; Leena Nahata
Journal:  Pediatrics       Date:  2016-03-02       Impact factor: 7.124

Review 9.  Consensus statement on the use of gonadotropin-releasing hormone analogs in children.

Authors:  Jean-Claude Carel; Erica A Eugster; Alan Rogol; Lucia Ghizzoni; Mark R Palmert; Franco Antoniazzi; Sheri Berenbaum; Jean-Pierre Bourguignon; George P Chrousos; Joël Coste; Sheri Deal; Liat de Vries; Carol Foster; Sabine Heger; Jack Holland; Kirsi Jahnukainen; Anders Juul; Paul Kaplowitz; Najiba Lahlou; Mary M Lee; Peter Lee; Deborah P Merke; E Kirk Neely; Wilma Oostdijk; Moshe Phillip; Robert L Rosenfield; Dorothy Shulman; Dennis Styne; Maïthé Tauber; Jan M Wit
Journal:  Pediatrics       Date:  2009-03-30       Impact factor: 7.124

Review 10.  What's in the pipeline? Drugs in development for autism spectrum disorder.

Authors:  Min Sung; Chee Hon Chin; Choon Guan Lim; Hwee Sen Alvin Liew; Chau Sian Lim; Espérance Kashala; Shih-Jen Weng
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-20       Impact factor: 2.570

View more
  1 in total

1.  Case Report: A Case of Intellectual Disability with Inappropriate and Challenging Sexual Behavior that was Treated with GNRH Analogues.

Authors:  Ferhat Yaylacı; Ali Gül
Journal:  Psychopharmacol Bull       Date:  2020-05-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.